Irene Becklund Sells 472 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 472 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $23.23, for a total transaction of $10,964.56. Following the transaction, the insider now owns 2,913 shares in the company, valued at $67,668.99. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Irene Becklund also recently made the following trade(s):

• On Monday, June 17th, Irene Becklund sold 472 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.10, for a total transaction of $11,375.20.
• On Friday, May 17th, Irene Becklund sold 943 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.50, for a total value of $13,673.50.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS traded up $0.27 during trading on Tuesday, hitting $23.11. The company’s stock had a trading volume of 7,124,404 shares, compared to its average volume of 7,398,993. The firm has a market cap of $4.96 billion, a price-to-earnings ratio of -2,310.50 and a beta of 1.08. The company has a 50-day moving average of $19.53 and a 200-day moving average of $14.51. Hims & Hers Health, Inc. has a 12 month low of $5.65 and a 12 month high of $25.74.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The firm’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.05) EPS. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HIMS. Citigroup lowered Hims & Hers Health from a “buy” rating to a “neutral” rating and lifted their target price for the company from $16.00 to $20.00 in a report on Wednesday, May 22nd. Bank of America raised their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a report on Thursday, June 13th. Seaport Res Ptn reissued a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. TD Cowen upped their price target on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $14.00 to $16.00 and gave the stock a “hold” rating in a report on Tuesday, May 7th. Seven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $18.36.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC acquired a new stake in Hims & Hers Health during the 2nd quarter worth $2,223,000. QRG Capital Management Inc. purchased a new stake in shares of Hims & Hers Health during the second quarter worth about $3,149,000. Gunderson Capital Management Inc. acquired a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $1,836,000. Cetera Advisors LLC acquired a new position in shares of Hims & Hers Health during the 1st quarter valued at $396,000. Finally, Farallon Capital Management LLC grew its holdings in Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after purchasing an additional 1,634,000 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.